VIP: Mechanism of Action

1. Alvo Receptor Primarios — VPAC1, VPAC2, and PAC1

VIP exerts its biological effects primariamente by binding to two specific G-protein-coupled receptors (GPCRs) pertencente a the Class B (secretin-like) family: [3]

• VPAC1 (VIPR1): Constitutively expresso(a) em the lung (alveolar type II cells), T-linfocitos, liver, and brain cortex.
• VPAC2 (VIPR2): Predominantly expresso(a) em musculo liso, the suprachiasmatic nucleus (SCN), pancreatic β-cells, and inducible in immune cells upon estimulacao.
• PAC1: VIP also liga-se a the PACAP receptor PAC1, but with significantly lower affinity (>500 nM). [8]

VIP-receptor interaction follows a “two-site” binding model: the N-terminal ectodomain (structured como um(a) “Sushi” domain) captures VIP’s central/C-terminal regions (residues 6–28), then the N-terminus of VIP (His1) ativa transmembrane domain 1 (TM1). [9]

2. Canonical Signaling — Gs/cAMP/PKA/CREB Pathway

In a maioria cell types, VIP binding desencadeia the exchange of GDP for GTP no(a) Gαs subunit, activating adenylyl cyclase (AC) and increasing intracellular cyclic AMP (cAMP). Elevated cAMP ativa Protein Kinase A (PKA), que phosphorylates cAMP response element-binding protein (CREB). This pathway drives surfactant production in lungs and insulin secretion no(a) pancreas. [10]

3. Alternative Signaling Pathways

• NF-κB Inhibition (PKA-Independent): In macrofagos and monocitos, VIP inibe nuclear translocation of NF-κB atraves de um(a) PKA-independent mechanism que previne fosforilacao of IκB and inibe IκB kinase (IKK), suppressing pro-inflamatorio(a) cytokine production. [11]
• Dual Gs/AC + Gq/PLC Pathway (Neurons): In GnRH neurons, VIP excitation requer ambos(as) Gs/AC/PKA and Gq/Phospholipase C (PLC) ativacao, levando a PIP2 depletion and inibicao of KCa3.1 channels. [12]
• Epac Pathway (β-Cells): In pancreatic β-cells, VIP signaling envolve ambos(as) PKA (closing ATP-dependent K⁺ channels, causing depolarization and Ca²⁺ influx) e o(a) Epac pathway (mobilizing intracellular Ca²⁺ stores to drive secrecao de insulina). [13]
• EGFR/HER2 Transativacao (Cancer): In certain cancer cells (lung, breast), VIP/PACAP signaling can transactivate EGFR and HER2, promoting cell growth and VEGF secretion. [14]

4. Tissue-Level Effects

Immunomodulacao: VIP inibe production of pro-inflamatorio(a) cytokines (TNF-α, IL-6, IL-12) and chemokines in macrofagos and microglia. It shifts T-cell diferenciacao from Th1 toward Th2 and Treg phenotypes, and downregula TLR2 and TLR4 expression on macrofagos and dendritic cells. [11]

Pulmonary System: VIP upregula choline phosphate cytidylyltransferase and C-Fos protein in alveolar type II (ATII) cells, increasing surfactant production. It acts as um(a) potente bronchodilator — 100-fold mais potente do que isoproterenol. [15]

Central Nervous System: In the suprachiasmatic nucleus (SCN), VIP synchronizes neuronal firing via VPAC2, producing long-lasting aumenta in electrical activity (2–4 hours) dependente de the clock gene Per1 and Kv3 channels. [16]

Metabolic System: VIP estimula secrecao de insulina in a dependente de glicose manner via VPAC2 receptors on pancreatic β-cells — negligible at baixo(a) glucose (protecting against hipoglicemia) but potente during hiperglicemia. [13]

5. Pharmacokinetics — Ultra-Short Half-Life

VIP has a serum meia-vida of aproximadamente 1–2 minutes, with rapido(a) degradacao by DPP-4 e outros(as) peptidases no(a) liver, kidneys, and lung. [5] Following IV administration, aproximadamente 45% of a dose distributes para o(a) lungs within 30 minutes. Apparent volume of distribuicao is ~14 mL/kg with a metabolic depuracao rate of ~9 mL/kg/min. [17]

6. Dose-Response Relationships

• CNS Firing Rate (SCN): 1 µM and 10 µM VIP produziu significant aumenta in SCN neuronal firing; 0.1 µM had no effect (threshold response). [16]
• Circadian Phase Shifting: Threshold ~100 nM, EC₅₀ ~500 nM, saturation at ~10 µM. [18]
• Neuroprotection (VIPR2 agonist LBT-3627): Bell-shaped dose-response — 2.0 mg/kg provided optimal neuroprotecao and Treg rescue in rat Parkinson’s models. [19]
• Antiviral Activity: 10 nM VIP provided maximal anti-SARS-CoV-2 effects in cell models; effects seen at 1 nM. [4]